News by Tag: Personalized Treatment


Where does the Potential Lie for Players in Whole Genome Sequencing?
January 8, 2013
Factors like easy availability, lower cost of whole genome sequencing (WGS) and widely publicized positive impact WGS has played in diagnosing cancer will make cancer diagnosis through WGS a profitable venture for players.
Significant Potential Underlines the US Personalized Cancer WGS Market
October 25, 2012
Despite high associated costs, the potential customer base for the US personalized cancer whole genome sequencing (WGS) market stands at a staggering figure of 881,667 persons, says RNCOS.
Rising Cancer Prevalence to Drive the US Personalized Cancer Sequencing Market
September 28, 2012
With an additional 1.63 Million new people expected to be diagnosed with cancer in 2012, the total number of cancer patients in the US is likely to reach an annoying figure of 16.5 Million by the end of the year, says RNCOS.
US Personalized Cancer Whole Genome Sequencing Market to Post 17.7% CAGR
September 21, 2012
Recognition of its role for aiding oncologists in designing life-saving personalized therapies against cancer has opened doors to a huge multi-billion dollar potential market to players, says RNCOS.